Japan· JP-1144400A1018
スルピリン水和物
A metamizole sodium product containing スルピリン水和物, registered in Japan, on the national reimbursement list. The same ATC class is registered in 8 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Metamizole sodium is registered in 8 of 19 countries.
Countries holding a registration under ATC N02BB02 (metamizole sodium), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 6 of them publish a price we can compare per daily dose
Metamizole sodium · ATC N02BB02
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of metamizole sodium costs, country by country.
Normalised to the WHO defined daily dose (3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Metamizole sodium · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$3.00
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- スルピリン水和物
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- N02BB02
- ATC class
- Metamizole sodium
- Defined daily dose
- 3 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for metamizole sodium.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metamizole sodium · interactions on record
5 records
5 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under N02BB02
Metamizole sodium, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ad98ab4e-d21e-495a-95fa-133fb80f4a24 GET /v1/drugs/ad98ab4e-d21e-495a-95fa-133fb80f4a24?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１０％２ｍＬ１管",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "1144400A1018",
"category": "注射薬",
"price_yen": null,
"generic_name": "スルピリン水和物",
"product_name_jp": null,
"therapeutic_class": "1144",
"transitional_expiry": null
}See everything about metamizole sodium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.